Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Industry News

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

November 21, 2016

News Industry News

GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

August 02, 2016

News Industry News

Gore Launches New 7.5 cm Length GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface

February 29, 2016

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Industry News

First Patients Enrolled in the Gore RELINE MAX Clinical Study

December 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Industry News

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

August 24, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

Extended Follow-Up of Multicenter Trial Demonstrates Continued Superiority of Bivalirudin to Heparin with and without Glycoprotein IIB, IIIA Inhibition in Patients with Acute Myocardial Infarction

September 15, 2014

News Industry News

New Study Assesses the Utility of Optical Coherence Tomography During Stent Implantation in Primary PCI

September 14, 2014

News Industry News

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

July 17, 2014

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Industry News

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

May 22, 2014

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Industry News

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

November 07, 2011

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

Advertisement

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

Gore Launches New 7.5 cm Length GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

First Patients Enrolled in the Gore RELINE MAX Clinical Study

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Extended Follow-Up of Multicenter Trial Demonstrates Continued Superiority of Bivalirudin to Heparin with and without Glycoprotein IIB, IIIA Inhibition in Patients with Acute Myocardial Infarction

New Study Assesses the Utility of Optical Coherence Tomography During Stent Implantation in Primary PCI

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content